In contrast, individuals with ALK-positive NSCLC who received first-generation ALK inhibitors as their initial treatment have a reported median PFS of 10.9 months22, suggesting potentially lower efficacy of ALK inhibitors in ALK-positive CRC compared to NSCLC. This evidence concerns the gene ALK and colorectal carcinoma.